Form 8-K - Current report:
SEC Accession No. 0001213900-18-000851
Filing Date
2018-01-25
Accepted
2018-01-25 08:00:25
Documents
9
Period of Report
2018-01-23
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT f8k012318_actiniumpharma.htm 8-K 26918
2 COMPANY UPDATE AND OUTLOOK FOR 2018 f8k012318ex99-1_actinium.htm EX-99.1 40132
3 KEY DECEMBER EVENTS AND THEIR RELEVANCE & COMPANY FACT SHEET f8k012318ex99-2_actinium.htm EX-99.2 18802
4 GRAPHIC ex99-1_001.jpg GRAPHIC 25154
5 GRAPHIC ex99-1_002.jpg GRAPHIC 62650
6 GRAPHIC ex99-1_003.jpg GRAPHIC 87824
7 GRAPHIC ex99-1_004.jpg GRAPHIC 104599
8 GRAPHIC ex99-2_001.jpg GRAPHIC 15755
9 GRAPHIC ex99-2_002.jpg GRAPHIC 410462
  Complete submission text file 0001213900-18-000851.txt   1060882
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 18546651
SIC: 2834 Pharmaceutical Preparations